A detailed history of Vise Technologies, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Vise Technologies, Inc. holds 21,544 shares of AZN stock, worth $1.45 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
21,544
Previous 17,217 25.13%
Holding current value
$1.45 Million
Previous $1.34 Million 25.04%
% of portfolio
0.22%
Previous 0.24%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$76.67 - $87.62 $331,751 - $379,131
4,327 Added 25.13%
21,544 $1.68 Million
Q2 2024

Aug 01, 2024

BUY
$66.81 - $80.83 $225,483 - $272,801
3,375 Added 24.38%
17,217 $1.34 Million
Q1 2024

May 15, 2024

BUY
$61.03 - $69.57 $57,551 - $65,604
943 Added 7.31%
13,842 $937,000
Q4 2023

Feb 07, 2024

BUY
$61.89 - $69.28 $14,791 - $16,557
239 Added 1.89%
12,899 $868,000
Q3 2023

Oct 31, 2023

SELL
$64.85 - $71.7 $127,689 - $141,177
-1,969 Reduced 13.46%
12,660 $857,000
Q2 2023

Aug 08, 2023

BUY
$69.91 - $75.81 $134,926 - $146,313
1,930 Added 15.2%
14,629 $1.05 Million
Q1 2023

May 10, 2023

BUY
$63.15 - $71.6 $88,978 - $100,884
1,409 Added 12.48%
12,699 $881,000
Q4 2022

Feb 09, 2023

BUY
$54.21 - $70.44 $77,466 - $100,658
1,429 Added 14.49%
11,290 $765,000
Q3 2022

Nov 14, 2022

BUY
$53.02 - $135.75 $25,926 - $66,381
489 Added 5.22%
9,861 $541,000
Q2 2022

Aug 15, 2022

BUY
$59.26 - $71.14 $257,603 - $309,245
4,347 Added 86.51%
9,372 $619,000
Q1 2022

Jun 08, 2022

BUY
$55.72 - $67.12 $279,993 - $337,278
5,025 New
5,025 $333,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $208B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Vise Technologies, Inc. Portfolio

Follow Vise Technologies, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vise Technologies, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vise Technologies, Inc. with notifications on news.